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Abstract
Background: The development of arsenical and diamidine resistance in Trypanosoma brucei is associated with loss of drug
uptake by the P2 purine transporter as a result of alterations in the corresponding T. brucei adenosine transporter 1 gene
(TbAT1). Previously, specific TbAT1 mutant type alleles linked to melarsoprol treatment failure were significantly more
prevalent in T. b. gambiense from relapse patients at Omugo health centre in Arua district. Relapse rates of up to 30%
prompted a shift from melarsoprol to eflornithine (a-difluoromethylornithine, DFMO) as first-line treatment at this centre.
The aim of this study was to determine the status of TbAT1 in recent isolates collected from T. b. gambiense sleeping
sickness patients from Arua and Moyo districts in Northwestern Uganda after this shift in first-line drug choice.
Methodology and results: Blood and cerebrospinal fluids of consenting patients were collected for DNA preparation and
subsequent amplification. All of the 105 isolates from Omugo that we successfully analysed by PCR-RFLP possessed the
TbAT1 wild type allele. In addition, PCR/RFLP analysis was performed for 74 samples from Moyo, where melarsoprol is still
the first line drug; 61 samples displayed the wild genotype while six were mutant and seven had a mixed pattern of both
mutant and wild-type TbAT1. The melarsoprol treatment failure rate at Moyo over the same period was nine out of 101
stage II cases that were followed up at least once. Five of the relapse cases harboured mutant TbAT1, one had the wild type,
while no amplification was achieved from the remaining three samples.
Conclusions/significance: The apparent disappearance of mutant alleles at Omugo may correlate with melarsoprol
withdrawal as first-line treatment. Our results suggest that melarsoprol could successfully be reintroduced following a time
lag subsequent to its replacement. A field-applicable test to predict melarsoprol treatment outcome and identify patients
for whom the drug can still be beneficial is clearly required. This will facilitate cost-effective management of HAT in rural
resource-poor settings, given that eflornithine has a much higher logistical requirement for its application.
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Introduction
Human African trypanosomiasis (HAT) or sleeping sickness is
caused by T. brucei gambiense and T. b. rhodesiense. The disease affects
36 countries in sub-Saharan Africa with Angola, DR Congo,
South Sudan, Uganda and Central African Republic as the most
affected [1]. Current figures indicate a decline in disease incidence
with an estimate of about 70,000 new cases annually compared to
approximately 500,000 cases reported in the past 5 years [1–4].
The emergence of strains resistant to the widely used first-line drug
melarsoprol has, however, negatively impacted on HAT manage-
ment. An increasing incidence of melarsoprol treatment failures
varying from 15%–30% has been reported in geographically
distant foci in sub-Saharan Africa [5–8]. In 2001 this resulted in
the replacement of melarsoprol with eflornithine (DFMO) as first-
line therapy for late stage T. b. gambiense for specific foci in north
western Uganda and Southern Sudan , DR Congo, and more
recently in Angola.
The P2 aminopurine transporter has been implicated as a
principal route of entry into trypanosomes for melamine-based
arsenical drugs [9] and diamidines [10–13]. Loss of the transporter
has consistently been shown to correlate with the emergence of
drug resistance in laboratory isolates [9,14–17]. Later reports
demonstrated that the loss of this transporter was the result of
deletion of, or point mutations in, the TbAT1 gene (AF152369)
that encodes this transporter [14,15]. TbAT1 alleles from
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laboratory derived resistant lines and wild-type trypanosomes
could be distinguished by RFLP analysis, based on changes to two
Sfa N1 sites in the gene as a result of two specific point mutations:
arginine to threonine at position 178 and asparagine to serine at
position 286 [14]. The same RFLP pattern was found in T. brucei
ssp. field isolates. A PCR/RFLP approach based on this
observation was used in a study on T. b. gambiense isolates from
Omugo in NW Uganda to demonstrate a correlation between the
presence of mutant TbAT1 alleles and occurrence of relapse after
melarsoprol treatment [18]. However, the observation of the
TbAT1 wild type pattern in 30% of confirmed melarsoprol
refractory isolates suggested that there could be other mechanisms
contributing to resistance and that the PCR-RFLP method may
not detect all melarsoprol relapses [7,18–20]. Nevertheless,
monitoring of the status of TbAT1 is of paramount importance
since several drugs rely on the P2 transporter for import.
The increased level of treatment failures at Omugo through the
1990s led to replacement of melarsoprol with eflornithine as first
line treatment for late stage HAT in this focus in 2001. In the
current study we collected T. b. gambiense-infected blood from
patients from the Omugo focus in NW Uganda, and from Moyo
district, a neighbouring focus where melarsoprol is still used. We
then carried out analyses using the PCR/Sfa NI RFLP method to
determine the current status of TbAT1 at both foci, and to show
whether the TbAT1 genotype correlates with melarsoprol
treatment outcome in Moyo. Patients admitted at both sites were
followed for up to 24 months post treatment for parasitological
examination to ascertain treatment outcome.
Materials and Methods
Ethics statement
This study received ethical clearance from the Uganda National
Council for Science and Technology. The protocol and consent
documents were approved by the Institutional Review Boards of the
National Livestock Resources Research Institute (NaLIRRI) and the
Uganda National Council for Science and Technology (UNCST).
Written consent was obtained from all participants before
inclusion in the study.
Study area and population
Field activities were carried out during the period August 2003-
August 2006 in areas of the Arua and Moyo districts, in North
Western Uganda (Figure 1). Arua district (latitude 2u309N, 3u509N
and longitudes 30u309E, 31u309E), which has recently been sub-
divided into three new districts; Arua, Terego-Maracha, and
Koboko, is bordered by the Republic of Sudan in the north, DR
Congo in the West, Yumbe district in the northeast, Nebbi district
in the South and Gulu district in the East. Before the current break
up, it was composed of six counties namely: Koboko, Maracha,
Terego, Ayivu, Vurra and Madi-Okollo. Omugo health centre,
the main sleeping sickness control centre, is located in Terego
county (Figure 1). Moyo district (latitude 31u159N and longitude
31u459E) is bordered by the River Nile in the south and east,
Sudan in the north, and Yumbe district in the west. It is composed
of Obongi and West Moyo counties. Moyo hospital, the sleeping
sickness control centre, is located in Obongi county. The main
occupation in the entire study area is subsistence agriculture.
Patient screening
Active surveillance of populations at risk of HAT was done at
designated screening centres in areas of active transmission as
determined from hospital records, by Mobile teams aided by
Sleeping Sickness Assistants (SSAs) and local leaders. Screening of
patients was done according to an established diagnostic tree in
use in northwest Uganda. All presenting persons were screened for
trypanosome antibodies with the Card Agglutination Test for
Trypanosomiasis (CATT). Antibody levels in these potential HAT
cases were also determined using 1/4 and 1/8 dilutions of blood
plasma for the individuals positive in the CATT whole blood test.
Persons found positive after plasma dilution were subjected to
parasitological diagnostic procedures as below.
Parasitological diagnosis
Parasitological methods for detection of trypanosomes were
carried out at the respective health units (Omugo Health Centre
andMoyo Hospital). Wet smears of gland aspirates from individuals
with swollen lymph nodes were examined for motile trypanosomes
under the microscope at 406magnification. In addition, blood was
collected by venipuncture into heparinised vacutainer tubes and
subjected to the Haematocrit Centrifugation Technique (HCT)
[21]. Presence of trypanosomes in the lymph aspirates or blood was
confirmation that the sero-reactive individual was indeed a HAT
case. A lumbar puncture was performed for collection of
cerebrospinal fluid (CSF) to check for central nervous system
(CNS) invasion by double centrifugation [22]. Prior to the
centrifugation, a 50 ml aliquot of CSF was used on the Rosenthal
chamber to estimate the white blood cell count (WBC). Patients with
demonstrated presence of trypanosomes in CSF or with an elevated
WBC .5/mm3 were considered to be late stage cases.
Individuals who were sero-reactive up to CATT 1/8 plasma
dilution but were parasitologically negative were asked to report
for re-testing after 3 months. All confirmed HAT individuals were
hospitalized for the duration of treatment. Those who consented
after description of the study were enrolled.
Treatment
Stage I patients at both health units were treated with
pentamidine isethionate (4 mg/kg body weight/day) for 10 days
administered intramuscularly. Stage II patients in Moyo were
Author Summary
Human African trypanosomiasis (HAT) manifests as a
chronic infection caused by Trypanosoma brucei gam-
biense, or as a more acute form due to T. b. rhodesiense.
Both manifestations occur in Uganda and melarsoprol use
against the former was jeopardised in the 1990s as reports
of reduced efficacy increased to the point where it was
dismissed as first-line treatment at some treatment
centers. Previous work to elucidate possible mechanisms
leading to melarsoprol resistance pointed to a P2 type
adenosine transporter known to mediate melarsoprol
uptake and previously shown to be mutated in significant
numbers of patients not responding to the drug. Our
present findings indicate that there is a low prevalence of
mutants in foci where melarsoprol relapses are infrequent.
In addition we observe that at the Omugo focus where the
drug was withdrawn as first line over 6 years ago, the
mutant alleles have disappeared, suggesting that drug
pressure is responsible for fuelling their spread. Thus
constant monitoring for mutants could play a key role in
cost-effective HAT management by identifying which foci
can still use the less logistically demanding melarsoprol as
opposed to the alternative drug eflornithine. What is
required now is a simple method for identifying such
mutants at the point of care, enabling practitioners to
make informed prescriptions at first diagnosis.
TbAT1 and Melarsoprol Treatment in Uganda
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treated with a melarsoprol schedule of 3 series of 4 daily injections,
each series separated by 7 days. In Omugo, eflornithine (DFMO;
400 mg/kg body weight/day) was administered intravenously with
4 daily infusions (100 mg/kg body weight every 6 hours) for 14
days. Upon completion of treatment, patients were discharged and
requested to return after 6, 12, and 24 months to monitor for
treatment success. Patients showing signs of infection by
microscopy or elevated cell white cell counts during follow up at
Moyo hospital were re-admitted and treated with DFMO.
Collection of trypanosome samples
Whole blood and/or CSF for molecular analysis were collected
within 2 hours of written consent, prior to treatment. A total of
222 patients were enrolled into this study: 121 from Moyo and 101
from Arua, including 52 Koboko, 24 from Terego, 6 from
Maracha, 5 from Madi-Okollo counties and 14 from the
neighbouring Yumbe district.
For each HAT case enrolled in the study, samples were
collected both as blood spotted on FTA cards and as whole blood
and/or CSF. Two ml of whole blood from each individual
collected by venipuncture was spotted (500 ml per spot) onto an
FTA card (Whatman), air dried and stored in a self-sealing plastic
bag at room temperature for later molecular analysis. Trypano-
some genomic DNA was extracted from whole blood and CSF
samples using a commercial kit (PUREGENE, Gentra Systems,
Minneapolis, USA) according to the manufacturer’s instructions.
In this form easy storage at room temperature was possible to
await transportation to the laboratory for completion of DNA
extraction, performed exactly as described [18] within 2 weeks of
addition of the sample to the cell lysis solution of the kit.
PCR amplification of TbAT1 677 bp fragment
Trypanosome DNA from a 2.0 mm disc punched from an FTA
card was extracted using the FTA purification reagent following
the manufacturer’s instructions (www.whatman.com/repository/
documents/s7/FTAProtocolBook602.pdf). The TbAT1 fragment
for RFLP analysis was amplified from extracted DNA by nested PCR
[18]. In the primary PCR, each DNA disc or 5 ml of genomic DNA
solution purified from whole blood/CSF was amplified in a total
volume of 25 ml PCR reaction containing a 16 custom PCR master
mix (Advanced Biotechnologies Ltd, UK). The oligonucleotide primer
pair TbAT1 ant-s (59-GCCCGGATCCGGCTGGTTTTT AGA
CAAAAGTGAT-39) and TbAT1 ant-as (59-GCCCCTCGAGCC
GCA TGG AGT AAG TCT GA-39) [14] and 1.25 units of Taq
polymerase (Promega) were added to the reaction performed in a
PTC-100 DNA engine (MJ Research, Waltham, MA, USA) under the
following conditions: initial denaturation at 94uC for 4 minutes;
denaturation at 94uC for 30 seconds, annealing at 50uC for
30 seconds, and extension at 72uC for 1 minute for 30 cycles with a
final extension at 72uC for 7 minutes. Genomic DNA of T. brucei strain
STIB 950 (a reference clone isolated from a bovine in Somalia,
resistant to berenil, isometamidium and quinapyramine) [23] and
sterile water (no template) were included in each run as a positive and
negative control respectively. 2 ml of primary PCR product was used as
template in a secondary PCR with oligonucleotide primer pair ATF-2
(59-CGCCGCACTCATCGCCCCGTT-39) and ATR-2 (59-CCA
CCGCGGTGAGACGTGAT-39) under similar conditions but the
annealing temperature was increased to 65uC [18]. Ten micro litres of
each secondary PCR product were analysed by electrophoresis on a
1% agarose gel stained with ethidium bromide (0.7 mg/ml) and
visualised under ultraviolet transilluminiscence. The band sizes were
determined by comparison with a standard 1-Kb molecular weight
DNA marker (Gene Ruler, Fermentas Life Sciences).
Whole genome amplification
To increase the PCR sensitivity of the DNA samples on FTA
cards (Whatman) and genomic DNA from whole blood or CSF,
Figure 1. Regional Map of Uganda showing the origins (Districts/Counties) of study participants.
doi:10.1371/journal.pntd.0000523.g001
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the whole genome amplification method was carried out on
selected samples as described [24] using a commercial kit
(GenomiPhi, Amersham Biosciences). Reactions were carried out
in triplicate for each individual sample following the manufactur-
er’s instructions. Briefly, a DNA sample was denatured prior to
amplification. To a DNA sample on an FTA card disc was added
10 ml of sample buffer in a sterile microfuge tube, which was
heated to 95uC for 3 minutes in a heating block and then cooled to
4uC on ice. Alternatively, to 1 ml of DNA sample from whole
blood or CSF (at least 1 ng/ml) was added 9 ml of sample buffer.
For each amplification reaction, 9 ml of reaction buffer was
combined with 1 ml of enzyme mix on ice added to the cooled
sample. The sample was then incubated at 30uC in a heating block
for 16–18 hours. Following the overnight incubation, the sample
was heated to 65uC for 10 minutes in a heating block to inactivate
the enzyme and immediately cooled to 4uC. The 3 separate
reactions for each individual sample were pooled. 1–2 ml of whole
genome amplified DNA was ready for use in PCR or kept at
220uC.
RFLP using Sfa NI
For each isolate with a successfully amplified TbAT1 677 bp
fragment, 5 ml of PCR product was digested with the Sfa NI
enzyme to determine the TbAT1 genotype [14,18]. The reaction
was carried out in a total volume of 20 ml containing NEBuffer 3
and 1 unit of Sfa NI enzyme (New England Biolabs). The reactions
were incubated at 37uC overnight and then analysed by gel
electrophoresis on a 2.5% Agarose gel stained with ethidium
bromide. The generated fragments were visualised under
Ultraviolet trans-illumination.
Results
TbAT1 amplification
Given logistical problems in collecting and processing infected
blood for PCR analysis [24,25], we used Whatman FTA cards to
collect blood spots from infected patients in the two foci, Omugo
and Moyo. In pilot experiments (data not shown) using infected
rodent blood we showed that the TBR multicopy PCR primers
can detect trypanosomes from blood down to a density of fewer
than 1 parasite per ml. With single copy genes such as TbAT1,
however, the limit of detection was 104 trypanosomes per ml of
blood (data not shown). From a total of 222 DNA samples from
patient blood and/or CSF, amplification of the TbAT1 677 bp
fragment by nested PCR was successful for 179 (80%) (Figs 2, 3).
Presence of trypanosomal DNA in 34 of the samples in which
TbAT1 PCR had failed was determined by PCR using the highly
sensitive T. brucei multi-copy locus primers TBR-F and TBR-R
[26] on a subset of 133 samples including 65 samples that were
already TbAT1 positive. Results revealed trypanosome DNA
positive samples for all except one sample of patient M169 from
Moyo indicating a possible absence of T. brucei DNA in that
sample. In order to increase the starting DNA content before
amplification of the single copy TbAT1, a whole genome
amplification kit (GenomiPhi, Amersham Biosciences) was used
on the problematic samples. Of the 68 initially TbAT1 PCR failed
DNA samples, 26 were successfully re-amplified for TbAT1 (n = 17
Omugo and n= 9 Moyo) using this approach, bringing the total of
TbAT1 successfully amplified samples to 179/222.
The entire 133 sample sub-set was also PCR amplified for the
T. brucei single copy Phospholipase C (PLC) associated microsat-
ellite. This was successful for 61 (45.8%) of the isolates. Thus, the
PCR success rate of the TBR multicopy locus was higher than that
of TbAT1, which was in turn higher than that of the single copy
PLC microsatellite. These results strongly suggest that the PCR
failed samples had a low DNA content below detection threshold
for TbAT1 in 42 isolates and for the single copy PLC microsatellite
in 72 isolates, probably due to low parasite densities. Attempts with
alternative unpublished primer sets that we routinely use to
amplify different TbAT1 fragments did not yield any signals from
these samples. However, complete loss or deletions in TbAT1 – as
was shown in some laboratory strains [27,28] and at least one field
isolate from Angola (stock K001) [18] – cannot be ruled out,
especially for the samples that failed PCR for TbAT1 but were
Figure 2. Electrophoretic analysis of PCR-RFLP products.
Representative Agarose gel results (A) TbAT1 677 bp PCR product of
the trypanosome isolates from patients at Omugo (lanes B,D,E,G,I,J,K
and N). The positive control (+) is a multidrug resistant clone STIB 950,
negative control (2) was sterile water, while M is a 1 Kb molecular
marker (Gene rulerTM, Fermentas, Life Sciences). (B) Sfa NI digest of the
isolates from Omugo TbAT1 677 bp fragments. TbAT1 wild type pattern
of 566 bp and 111 bp fragments was displayed by all isolates from
Omugo (lanes 1–10, 12–14), while the positive control (STIB 950)
displayed the mutant genotype of 435 bp and 242 bp.
doi:10.1371/journal.pntd.0000523.g002
Figure 3. PCR/RFLP patterns of selected samples from Moyo.
U=undigested 677 bp fragment; W=wildtype pattern (STIB777S);
M=Mutant (STIB777R); samples 1–11 are from patients M058, M052,
M106, M048, M103, M074, M047, M044, M069, M062, and M031
respectively. Note the mutant pattern displayed in lanes 3, 5, 9, and the
mixed genotype in lanes 6 and 10.
doi:10.1371/journal.pntd.0000523.g003
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successfully amplified for the single copy PLC microsatellite (n = 5
Omugo and n= 7 Moyo).
PCR/Sfa NI RFLP analysis for TbAT1 genotype
The analysis of the TbAT1 677 bp fragment for each of the 91
isolates from Omugo by digestion with Sfa NI revealed exclusively
the wild type banding pattern (566 bp and 111 bp; Fig 2) identical
to the pattern displayed by the melarsoprol-sensitive T. brucei stock
STIB 777S [14]. This suggested the patients were infected with
trypanosomes of TbAT1+/+ wild type genotype, an indication that
they were melarsoprol-sensitive trypanosomes. Successful analysis of
74 samples from Moyo, where melarsoprol is still the first line drug,
revealed that 61 displayed the wild-type genotype while 6 were
homozygous for the mutant allele and 7 had a mixed pattern of both
mutant and wild-type TbAT1 (see Fig 3 for representative patterns).
Patient follow up for determination of treatment
outcome
Pentamidine isethionate was used for treatment of Stage I
patients at both health units, whereas stage II HAT was treated
with melarsoprol in Moyo and with eflornithine in Omugo (see
Materials and Methods).
Follow-up was performed according to established National
program guidelines at 6, 12 and 24 months. A total of 188 out of the
222 (85%) patients included in this study were followed up at least
once. Of these, 7/31 (2 from Omugo and 5 from Moyo) were re-
admitted 6–24 months after Pentamidine treatment and were
confirmed as stage II cases as demonstrated by the presence of
trypanosomes in CSF (5/7) coupled with elevated white cell counts
(7/7) compared to when they were first admitted. TbAT1
genotyping was only possible for 2 samples from Moyo and showed
mixed and wild-type patterns, respectively. Given the known
irrelevance of TbAT1 to DFMO (eflornithine) treatment outcome,
follow up results for this drug are beyond the scope of this paper and
will be discussed elsewhere (manuscript in preparation).
Melarsoprol relapses could only be investigated at Moyo where
the drug is still first-line. Out of 101 samples collected, 61 were
wild type, 7 mutant and 3 had mixed genotype, while no
amplification was possible from the remaining 27. Nine out of the
101 (9%) stage II patients were readmitted 6–12 months post-
treatment, with trypanosomes in the CSF and cell counts ranging
7–248/mm3 (Table 1). In 6 of the relapses, the white cell counts
had declined from those at initial admission although trypano-
somes persisted within the CSF. TbAT1 analysis of DNA samples
recovered from the CSF revealed that 5 were mutant and 1
possessed the wild-type. No signals were obtained from the
remaining 3 samples, probably due to limiting amounts of parasite
DNA therein. Assuming that the mixed allelotypes observed were
either heterozygotes or mixed infections of equal numbers of
homozygous wild type and homozygous mutants, the overall gene
frequencies are 0.865 (122+6/148) for wt and 0.135 (14+6/148) for
mut. It would therefore follow that the probability P of having by
chance at least 5 out of 6 melarsoprol relapse samples as mut (as
was observed in this study), is 0.00024. Thus it is highly significant
to have 5 mut patterns in the relapse group, a further evidence to
incriminate TbAT1 involvement in melarsoprol relapse.
Discussion
While mutations in TbAT1 have clearly been implicated in drug
resistance of T. b. brucei in the lab, the role of TbAT1 in treatment
failures with T. b. gambiense in the field is unclear. It was recently
shown in Southern Sudan, where melarsoprol had also been
replaced with eflornithine in 2001, that trypanosomes in
circulation in 2003 only had the so called wild type alleles at the
Sfa N1 RFLP sites [29]. This led the authors to conclude that it
was unlikely that this resistance allele had been in circulation in
2001, and that it was possible that reasons other than loss of P2
activity had been responsible for the melarsoprol treatment failures
there. However, that study could not rule out the possibility that
removal of melarsoprol as first line treatment led to loss of a
selective pressure on circulating trypanosomes and that a fitness
cost associated with mutant TbAT1 alleles led to loss of those alleles
from the population. There was no base-line data available on
genotypes found in Southern Sudan when melarsoprol was in use
to address this hypothesis.
Given that data was available for allelotypes in Omugo during
the time when melarsoprol treatment failure was prevalent (see
Table 2), it was of considerable interest to determine whether the
so-called mutant allele that was prevalent at that time was still
present several years after melarsoprol selection pressure had been
withdrawn. We also generated allelotype data from a second site in
Northern Uganda (Moyo) where melarsoprol has remained in use
until today.
The Sfa N1 RFLP profile previously reported [14,18,20]
comprises either a pattern yielding bands of 566 bp and 111 bp
in wild-type parasites, or of 435 bp and 242 bp in the resistant
parasites. Of the 105 samples from Omugo where melarsoprol has
Table 1. Melarsoprol relapse patients at Moyo Hospital and
the TbAT1 genotypes in samples recovered from their CSF.
Code
Initial CSF
Cells/Tryps
Relapse
after
CSF
Cells/Tryps
TbAT1
genotype
M048 74/+ 06 months 07/+ Wildtype
M059 240/+ 06 months 104/+ Mutant
M064 210/+ 06 months 158/+ Mutant
M073 56/+ 06 months 132/+ Mutant
M094 36/+ 06 months 42/+ Failed PCR
M103 240/+ 06 months 84/+ Mutant
M106 210/2 06 months 158/+ Mutant
M139 41/2 12 months 248/+ Failed PCR
M141 36/+ 06 months 42/+ Failed PCR
Tryps = trypanosomes; +=Trypanosomes present; 2= Trypanosomes not
observed. CSF cells counts are indicated as cells/ml.
doi:10.1371/journal.pntd.0000523.t001
Table 2. Melarsoprol relapse rates and TbAT1 genetic status,
1998 to present study.
Omugo
1998a
Omugo
by 2006
Moyo
by 2006
Stage II patients 65 90 101
Melarsoprol relapses 43 n.a.b 9
Frequency of TbAT1 mutant alleles:
i) - in newly infected patients 36% 0% 12%
ii) - in relapse patients 70% n.a.b 83%
Total 58% 0% 18%
aData from [13].
bUse of melarsoprol discontinued in 2001.
doi:10.1371/journal.pntd.0000523.t002
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not been used since 2001, only the wild type pattern was observed
in specimens from which TbAT1 did amplify. By contrast, at
Moyo, where melarsoprol is still in use, of 74 amplified TbAT1
samples, 61 isolates displayed the wild-type pattern, 6 had the
mutant (resistant) pattern and seven showed a mixed pattern.
To determine if a difference existed between the above TbAT1
results obtained from Omugo and Moyo, the samples with the
observed TbAT1 allele types were grouped separately or combined
and analysed using the Chi squared test. The results showed a
significant difference (x2 = 19.9, P= 0.000 and x2 = 18.1, P= 0.000
respectively). This suggests a significant difference in allelotype
compositions at the two sites, namely the presence of TbAT1
mutant alleles in Moyo and their absence in Omugo.
Our results seem to suggest that the P2 transporter gene, in its
mutant form, actually carries a fitness cost such that mutants could
disappear from a locality once the selective pressure exerted by
melarsoprol is removed (see Table 2 for prevalences of mutant
genotypes at two time points, before and after melarsoprol
withdrawal).. Interestingly, no fitness cost to the absence of a
functional TbAT1 transporter was observed under in vitro
laboratory conditions; on the contrary, tbat12/2 null mutant
trypanosomes grew even faster than TbAT1+/+ parasites in vitro
[30] and the tbat12/2 parasites were as infective as the parental
line to laboratory rodents [15]. Definitive proof is lacking, but the
disappearance of this allele from Omugo has coincided with the
removal of melarsoprol as first line treatment. At the same time,
the persistence of TbAT1 mutant alleles at Moyo, where
melarsoprol is still in use, and the correlation between TbAT1
mutant alleles and melarsoprol treatment failure, would also
support this hypothesis.
If it is the case that removal of melarsoprol selection pressure is
associated with loss of mutant TbAT1 alleles that contribute to
drug resistance, this would indicate that melarsoprol could
eventually be suitable for treatment in many areas where failures
have led to its withdrawal. In order to achieve this, it would be
necessary to make a rapid diagnosis of the status of the P2
transporter in parasites from patients in a given focus. This could
be achieved, for example, using the fluorescence test for
melarsoprol resistance [31]. Application of tests such as this could
lead to a rational choice of treatment with melarsoprol, or
eflornithine. Indeed given its toxicity, melarsoprol can not be the
drug of choice; its continued use could nevertheless delay
resistance to the latter that is likely to appear fast due to its being
just a trypanostatic drug. Coupled to alternate use of the two
drugs, the nifurtimox-eflornithine combinations currently under
consideration [32] would minimise the prospects of treatment
failure and concomitantly reduce the risk of spreading drug
resistance.
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